Agenus price target lowered to $18 from $42 at B. Riley

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Agenus to $18 from $42 and keeps a Buy rating on the shares post the Q2 report. The firm is now “conservatively modeling” post-Phase III U.S. second-line colorectal cancer market entry in 2028. It says Agenus is “down but not out.”